228 Studies Now Enrolling
Menu
Search
Medical Condition
Displaying 1 - 59 of 59
Condition: Cancer / Bladder Cancer
Investigator: Joel DeCastro, MD, MPH
Status: Closed
This research study will investigate an experimental, unapproved drug that will be given two different ways; as an injection in the bladder wall after bladder tumor resection surgery (or TURBT) and then as an intravesical instillation (fluid inserted in the bladder…
Condition: Cancer / Bladder Cancer
Investigator: Christopher Anderson, MD
Status: Closed
This study is for patients who have bladder cancer that has not invaded muscle tissue and who have been treated with one or more surgical resections and Bacillus Calmette-Guerin or BCG, which was directly given into the bladder before. The main purpose of this trial is to show that durvalumab is…
Condition: Cancer / Bladder Cancer
Investigator: Andrew Lenis, MD
Status: Closed
This study is being done to answer the following question: Can we lower the chance of your bladder cancer growing or spreading by using one type of chemotherapy instilled in the bladder, Gemcitabine and Docetaxel, instead of the usual therapy? The usual approach for patients who are not in a…
Condition: Cancer / Bladder Cancer
Investigator: Joel DeCastro, MD, MPH
Status: Closed
The study is part of a research program to assess the efficacy of the drug nab-rapamycin, a biologic mTOR inhibitor. The purpose of the study is to assess the response rate, as well as, the safety of administering nab-rapamycin in combination with gemcitabine directly into the bladder in an effort to treat…
Condition: Cancer / Bladder Cancer
Investigator: Joel DeCastro, MD, MPH
Status: Closed
The purpose of this study is to look at a new treatment for non-muscle-invasive bladder cancer. This new form of paclitaxel, a drug currently used by injection into a vein to treat various types of cancer, is designed to be instilled (injected) into the urinary bladder with a catheter (tube)…
Condition: Cancer / Bladder Cancer
Investigator: Joel DeCastro, MD, MPH
Status: Closed
This is a Phase 1 study (the first time this treatment is being tested in humans) of an anti-cancer study drug called as PF-07225570. This study drug works on stimulating certain cells in the immune system. The study will test different doses that increase (dose escalation) and at the appropriate time, additional patients will be enrolled to evaluate this…
Condition: Cancer / Bladder Cancer
Investigator: Joel DeCastro, MD, MPH
Status: Closed
We are doing this research to find out the safety, toxicity, and efficacy of intravesical Cabazitaxel, Gemcitabine, and Cisplatin (CGC) in the treatment of non-muscle-invasive urothelial carcinoma of the bladder that has recurred despite BCG use. The purpose of finding the maximum tolerable dose is important for future use of…
Condition: Cancer / Bladder Cancer
Investigator: Joel DeCastro, MD, MPH
Status: Closed
The purposes of this clinical study are: To evaluate the safety and tolerability of up to 2 drug release periods of GemRIS for up to 7 days per drug release period To evaluate the pharmacokinetics (the study of the bodily absorption, distribution, metabolism, and excretion of the drug) of gemcitabine and a gemcitabine-related metabolite (product after…
Condition: Cancer / Bladder Cancer
Investigator: Christopher Anderson, MD
Status: Closed
This research is being done to study the effects, safety, and tolerability of the study drugs Nivolumab and Urelumab when given to people with advanced bladder cancer that has spread into the muscle tissue, also called Muscle-Invasive Urothelial Carcinoma of the Bladder (MIBC). Specifically, this…
Condition: Cancer / Bladder Cancer
Investigator: Emerson Lim, MD
Status: Closed
The purpose of this study is to test how well the drug works, safety, and side effects of the experimental drug called BMS-986205. BMS-986205 will be added to another cancer medicine called nivolumab plus chemotherapy for participants who have bladder cancer that has grown into the muscle wall of the …
Condition: Cancer / Bladder Cancer
Investigator: Mark Stein, MD
Status: Closed
This clinical trial is for patients who have cancer of the urinary system (urothelial cancer, including cancer of the bladder, renal pelvis, ureter or urethra) that has spread to nearby tissues or to other areas of the body who have already been treated with a kind of anticancer drug called an immune checkpoint inhibitor (CPI…
Condition: Cancer
Investigator: Joel DeCastro, MD, MPH
Status: Closed
This study is designed to obtain information on the safety and the effectiveness of an experimental drug called Vicinium when it is given to human subject(s)/participant(s) with bladder cancer that has not spread to the muscle of the bladder. Vicinium is part of an antibody connected to a protein…
Condition: Cancer
Investigator: Charles Drake, MD
Status: Closed
The purpose of this study is to find out what effects, whether good or bad, that the combination of MOXR0916 plus atezolizumab has on you and your bladder cancer (locally advanced or metastatic urothelial cancer). Atezolizumab is approved in the United States for subjects with bladder cancer that…
Condition: Cancer
Investigator: Mark Stein, MD
Status: Closed
This is a research study for a vaccine called GEN-009. The main purpose of this study is to obtain information on the safety of GEN-009 and how it may activate the immune system to fight cancer. GEN-009 is a personalized vaccine. Each vaccine is made specifically for each person in the study. The vaccine is made after taking and testing cells from your…
Condition: Cancer
Investigator: Emerson Lim, MD
Status: Closed
This research study is designed to determine whether the study drugs are effective in treating muscle invasive bladder cancer in patients whose cancer did not stop, or whose cancer returned after being treated with other drugs, and study what kind of side effects are caused by these study drugs. To do this, a group of patients…
Condition: Cancer / Bladder Cancer
Investigator: Joel DeCastro, MD, MPH
Status: Closed
This study is being conducted to evaluate the performance of the AssureMDx test for the detection of bladder cancer in patients presenting with hematuria.
Condition: Cancer / Solid Tumors
Investigator: Mark Stein, MD
Status: Closed
The purpose of this study is to test the safety, tolerability, and effectiveness (how well these drugs work together) of NKTR-214 given in combination with KEYTRUDA or TECENTRIQ. We want to find out what effects, good or bad, the study drug has on the body and cancer when combined with KEYTRUDA or TECENTRIQ. The study will recruit participants at least 18…
Condition: Cancer
Investigator: Brian Henick, MD
Status: Closed
The purpose of this research study is to learn more about an experimental personalized vaccine that has two components called GRT-C901 and GRT-R902. We will learn more about the effects of this vaccine on your cancer when used together with approved medications that activate the immune system, nivolumab (Opdivo) as well as ipilimumab (Yervoy), which are…
Condition: Cancer
Investigator: Karie D. Runcie, MD
Status: Closed
The purpose of this study is to evaluate the efficacy of the study drug, XL092 alone and/or in combination of other study drugs such as with nivolumab, nivolumab plus ipilimumab, or nivolumab/relatlimab fixed-dose combination as a potential anticancer therapy to treat people with locally advanced or metastatic cancers including advanced renal cell cancer,…
Condition: Cancer
Investigator: Ojas Shah, MD
Status: Closed
The purpose of this study is to evaluate the effect and safety of MitoGel on patients with Upper TractUrothelial Carcinoma (UTUC). This research study is being done because this is a potentially beneficial new treatment for Low Grade UTUC. Mitomycin C (MMC) is FDA approved for other clinical indications and commercially available for the treatment of…
Condition: Cancer
Investigator: Benjamin Herzberg, MD
Status: Closed
The purpose of this study is to learn how well RP-1664 alone works to treat advanced solid tumor. RP-1664 has not been approved by the Food and Drug Administration (FDA). RP-1664 has not been given to humans prior to this study. Cancers include: bladder cancer, breast cancer, colon and rectal cancer, esophageal cancer,…
Condition: Cancer
Investigator: Edmond Chan, MD
Status: Closed
The main purpose of the study is to find the optimal dose of HRO761 alone or in combination with tislelizumab or irinotecan that can be given to people with certain cancer types called MSI high or dMMR. The new drug being tested in the study, HRO761, is an oral drug that is called a targeted medicine: this means that it targets particular processes which…
Condition: Cancer
Investigator: Benjamin Izar, MD
Status: Closed
This is a research study to determine how safe and effective a new treatment, called IMC-F106C, is for treating advanced cancers. This study is the first time the study drug is being tested in people. IMC-F106C has been developed to treat cancer by activating the body's own immune system to fight the tumor. The study drug has 2 parts. The first part,…
Condition: Cancer
Investigator: Mark Stein, MD
Status: Closed
The purpose of this study is to assess whether an investigational drug, called XmAb808, given in combination with pembrolizumab, has any effects on your cancer, to determine the best dose of XmAb808 to treat your cancer, and if it is safe and well-tolerated. XmAb808 is an investigational drug being developed for the treatment of advanced solid tumors. An…
Condition: Cancer
Investigator: Brian Henick, MD
Status: Closed
The purpose of this study is to determine the safety and effectiveness of two drugs, either rituximab or tocilizumab, in patients who develop side effects while on treatment with immunotherapy requiring prolonged steroids. Immune-related side effects are caused by activation of the immune system from treatment with immunotherapy. Both rituximab and…
Condition: Cancer
Investigator: Mark Stein, MD
Status: Closed
This study is being done to answer the following question: What is the highest dose of BAY 1895344 that can be given safely in combination with cisplatin and gemcitabine in patients with advanced solid tumors, including urothelial carcinoma? We are doing this study because we want to find out if this approach is better or worse than the usual approach for…
Condition: Cancer
Investigator: Benjamin Herzberg, MD
Status: Closed
The study is being done to learn how safe and effective the study drug, RP-3500, is when given with either niraparib or olaparib to treat advanced cancer. Niraparib and olaparib belong to a group of drugs called PARP inhibitors. These drugs are designed to block an enzyme called PARP which may stop cancer cells from growing. RP 3500 belongs to a class of…
Condition: Cancer
Investigator: Mark Stein, MD
Status: Closed
The purpose of this study is to test the safety and effectiveness of ASKG915 at different dose levels to find out what effects, good or bad, this study drug has on you and your cancer. ASKG915 is an experimental treatment that is being developed for treating people with advanced solid tumors. Experimental means the study drug has not been approved for the…
Condition: Cancer
Investigator: Brian Henick, MD
Status: Closed
This phase Ib trial studies the side effects of nivolumab and to see how well it works in treating patients with autoimmune disorders and cancer that has spread to other places in the body or cannot removed by surgery. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the…
Condition: Cancer
Investigator: Alexander Wei, MD
Status: Closed
The purpose of this study is to evaluate the safety profile of IDE196 (an investigational drug), in enrolled subjects to find out if it is safe and possibly helpful in patients with certain cancers such as metastatic uveal melanoma, cervical cancer, lung cancer, lung cancer, pancreatic cancer, stomach cancer, bladder cancer,…
Condition: Cancer
Investigator: Ran Reshef, MD
Status: Closed
The goal of the study is to learn if it is safe to give genetically changed T cells in combination with standard-of-care chemotherapy (fludarabine and cyclophosphamide) and IL-2 (aldesleukin) to patients with solid tumors that have grown or returned after being treated. Researchers also want to learn about possible side effects of the study drug and if the…
Condition: Cancer / Lung Cancer
Investigator: Catherine Shu, MD
Status: Closed
The purpose of this study is to assess the effects, good or bad, of atezolizumab and tiragolumab given with or without chemotherapy (in this study, chemotherapy will be a combination of either paclitaxel with carboplatin, pemetrexed with carboplatin or cisplatin, or gemcitabine with carboplatin or cisplatin) on patients who are able to have surgery to…
Condition: Cancer
Investigator: Matthew Ingham, MD
Status: Closed
The goal of this study is to determine at what dose the study treatment (ASP9801) is safe and tolerated in study participants with cancer who have tumors that cannot be removed (unresectable) or have spread (metastasized) to a different part of the body. This will be done by enrolling small groups of participants to receive different doses of the study…
Condition: Cancer
Investigator: Prabhjot Mundi, MD
Status: Closed
The purpose of this study is to test the safety of different doses of BA3011 and to find out what effects, good and/or bad, that it has on advanced solid tumor cancers that have tested positive for the AXL protein. AXL is a protein found on certain types of cancer cells. This research study will choose the dose amount that should be studied in the future…
Condition: Cancer / Prostate Cancer
Investigator: Mark Stein, MD
Status: Closed
The purpose of this study is to find out whether delivering SBRT to the prostate, combined with the study drug atezolizumab, is a safe and effective treatment when given in combination with abiraterone, prednisone, and Lupron (the standard treatment for this disease). In addition, the researchers want to find out whether the study treatment works better…
Condition: Cancer
Investigator: Benjamin Izar, MD
Status: Closed
This research study is studying a drug called AGEN2373 as a possible treatment for advanced cancer. The study drug targets cells that are a part of the body's immune system to block a protein called anti-CD137 agonist antibody. Blocking this protein is believed to improve the ability of your immune system to fight your cancer. This drug has been tested in…
Condition: Cancer
Investigator: Mark Stein, MD
Status: Closed
INCB106385 and INCMGA00012 are drugs being studied by Incyte Corporation for use in the treatment of advanced cancer. These study drugs are known as immune therapies, which are designed to help your immune system become more active and possibly fight your cancer. INCB106385 will be tested either alone (monotherapy) or in combination with INCMGA00012. The…
Condition: Cancer
Investigator: Benjamin Izar, MD
Status: Closed
The purpose of the study is to help the Sponsor understand whether study drugs, AB308 together with zimberelimab (also called AB122) can be safely given to patients with advanced cancers. Zimberelimab (AB122) is an investigational drug that has been shown in animal studies to slow or stop the growth of some cancers by using the immune system. AB308 is an…
Condition: Cancer
Investigator: Shaheer Khan, DO
Status: Closed
The purpose of this study is to see if the investigational drug MPT-0118 is effective in treating people with cancer. This is the first time the study drug, MPT-0118, will be given to humans. MPT-0118 will be given alone (monotherapy) and in combination with Keytruda (pembrolizumab). Pembrolizumab is approved by the FDA to treat certain types of cancer. MPT…
Condition: Cancer
Investigator: Dawn Hershman, MD
Status: Closed
In this study, we are evaluating a 30-minute pharmacist-led video consultation to provide education about your new oral anti-cancer drug (OACD) and help identify and manage potential drug-drug interactions alongside your oncologist. Our study aims to evaluate a one-time, 30-minute pharmacist-led video visit among patients starting OACDs. During the video…
Condition: Cancer
Investigator: Bret Taback, MD
Status: Closed
Surgery is the main treatment for many cancer conditions. In many elderly patients, surgery can greatly affect physical condition, and the ability to return to pre-surgery levels of physical functioning. By providing some simple pre-surgical recommendations, it may be possible to improve the rate of recovery from surgery and the possibility that patients…
Condition: Cancer
Investigator: Richard Carvajal, MD
Status: Closed
The purpose of this study is to assess the safety and tolerability of an experimental study drug called ulixertinib (BVD-523) in the treatment of advanced cancer that shows certain genetic alterations (changes in the DNA) called MEK or atypical BRAF alterations and is getting worse. Experimental means that ulixertinib has not received authorization to be…
Condition: Cancer
Investigator: Benjamin Izar, MD
Status: Closed
The purpose of this clinical trial is to find a safe and tolerated dose of the study treatment COM701 in combination with BMS-986207 and nivolumab for the treatment of advanced solid tumors. These drugs are being developed to fight cancer by using your immune system to fight the cancer cells (known as immunotherapies). These study drugs are also known as…
Condition: Cancer
Investigator: Melissa Accordino, MD
Status: Closed
Many patients with metastatic cancer experience frustration with the large number and complex scheduling of their medications. This study will help us find out how much pill burden exists in patients with advanced cancer, and how a smartphone app can help patients take their medications as their providers prescribe. Results of this study may help us figure…
Condition: Cancer
Investigator: Matthew Ingham, MD
Status: Closed
The purpose of this study is to: test the safety of the study drug and see how your body handles it, find the highest dose of the study drug that can be given alone or in combination with embrolizumab (MK-3475) with the least risk of serious side effects. The study drug is called MK-2118. Solid tumor or lymphoma cancers include: …
Condition: Cancer
Investigator: Mark Stein, MD
Status: Closed
The purpose of this study is to learn about the study drug RTX-240. This study is the first time RTX-240 will be used in people. Researchers will be studying the safety and effectiveness of RTX-240 in patients with certain types of cancer. The study will check if RTX-240 causes any changes in your health (or side effects), how well it may work at treating…
Condition: Cancer
Investigator: Mark Stein, MD
Status: Closed
This study will test the investigational drug, DS-7300a, for the first time in humans. DS-7300a is an antibody-drug conjugate (ADC) being developed as an anti-cancer agent. ADCs are made up of a monoclonal antibody chemically linked to a drug. The monoclonal antibody binds to specific proteins or receptors found on certain types of cells, including cancer…
Condition: Cancer / Solid Tumors
Investigator: Mark Stein, MD
Status: Closed
The primary purpose of this research study is to learn the safety and tolerability of the investigational drug, XmAb 22841 when given alone or in combination with another drug called pembrolizumab. You will be assigned to either receive XmAb22841 alone or in combination with pembrolizumab and you will know what treatment you are receiving. This study will…
Condition: Cancer
Investigator: Mark Stein, MD
Status: Closed
GEN-011 is an experimental treatment being evaluated in adult patients with advanced cancer. GEN-011 is a T cell therapy made specific to each patient, using the patient's own circulating immune cells. First, the cancer proteins that are already recognized by the patient's T cells are found. Then, immune cells that recognize these cancer proteins are…
Condition: Cancer
Investigator: Matthew Ingham, MD
Status: Closed
The purpose of this study is to test the safety and effectiveness of the study drug, BI 1387446, given alone or combined with the study drug, BI 754091, in subjects with different types of advanced cancer. BI 1387446 will be injected directly into at least one tumor site. BI 754091 will be given by intravenous (IV) infusion, which is a slow injection of the…
Condition: Cancer
Investigator: Naiyer Rizvi, MD
Status: Closed
The purpose of this research is to learn about the effects of 2 new investigational drugs, PF-04518600 and PF-05082566. PF-04518600 and PF-05082566 are antibodies (a type of protein) which have been shown to stimulate the immune system. Research has shown that an immune response like this can work against tumor cells to slow tumor growth by causing tumor…
Condition: Cancer / Solid Tumors
Investigator: Brian Henick, MD
Status: Closed
GSK3359609 is a drug that is a type of antibody. It is a kind of immunotherapy that targets the ICOS (anti-Inducible T cell Co-Stimulator) protein present on specific immune cells. ICOS is a cell receptor that enhances the immune response to foreign bodies, and which is expected to help your immune system find and fight cancer cells. It will also be called…
Study of Drug that May Reduce Risk of Blood Clot Development in Cancer Patients Who Are Able to Walk
Condition: Cancer
Investigator: David Diuguid, MD
Status: Closed
The purpose of this study is to see if rivaroxaban is useful in reducing the risk of patients developing blood clots while undergoing cancer treatment. The safety of rivaroxaban will also be studied. Cancer diagnoses include: pancreas, lung, stomach, colon, rectum, bladder, breast, ovary, renal, or lymphoma.
Condition: Cancer
Investigator: Richard Carvajal, MD
Status: Closed
This study is for patients with incurable cancers such as, metastatic non-small cell lung cancer, melanoma, renal cell carcinoma, triple negative breast cancer, colorectal cancer, head and neck cancer, castrate resistant prostate cancer and bladder cancer. The purpose of this study is find out whether an investigational (…
Condition: Cancer
Investigator: Naiyer Rizvi, MD
Status: Closed
This study is an exploratory biopsy sample study. Its purpose is to better understand why your metastatic cancer has progressed and stopped responding to checkpoint inhibitors. The information gained from this study may be valuable for understanding the mechanisms that cause resistance to immunotherapy. Cancers include: bladder…
Condition: Cancer
Investigator: Richard Carvajal, MD
Status: Closed
This study is for patients with tumors that cannot be removed (unresectable) or has spread (metastasized) to a different part of the body. The main purpose of the study is to determine at what dose the study drug is safe and tolerated. The study drug is called ASP8374. The study also wants to see how ASP3874 is processed in the blood. When the safe dose is…
Condition: Cancer
Investigator: Naiyer Rizvi, MD
Status: Closed
This study is for individuals with advanced cancers. Only patients with non-small cell lung cancer (NSCLC), squamous cell carcinoma of the head and neck (SCCHN), colorectal cancer (CRC), bladder cancer, ovarian cancer, esophageal cancer, gastric cancer, or renal cell carcinoma will be enrolled. The purpose of the study is to…
Condition: Cancer / Lymphoma
Investigator: Ran Reshef, MD
Status: Closed
The purpose of this study is to find out if the experimental combination of lenzilumab (an antibody that blocks the cytokine GM-CSF) and axicabtagene ciloleucel (which is identical to the FDA-approved CAR-T cell product YESCARTA) helps in protecting patients from side effects of axicabtagene ciloleucel. While axicabtagene ciloleucel has been approved by the…
Condition: Cancer / Solid Tumors
Investigator: June Hou, MD
Status: Closed
The study drug (TSR-042) in this study is designed to stop cancer from growing by helping your immune system recognize and fight the cancer. The Study Drug is designed to help your immune system by attaching to a protein called PD-1 and stopping one of the signals that keeps your immune system from recognizing the cancer. This may help your immune system…